Icosavax gains after update on RSV vaccine trial

Icosavax

31/03/2023 17:03

** Shares of vaccine developer Icosavax Inc  ICVX.O  rise
~8% to $6.06
    ** Late on Thursday, co said it has completed dosing in an
early-stage study of its experimental vaccine candidate,
IVX-A12, for respiratory syncytial virus (RSV)
    ** Adds that it plans to announce top-line data for the
trial in Q2 of this year, followed by planned initiation of a
mid-stage study in H2 of 2023
    ** Co also expects readout of 12-month data on immune
response from an early-stage trial of another RSV vaccine
candidate, IVX-121, in mid 2023
    ** ICVX shares have gained ~24% YTD 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))